A carregar...
HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor
Activating mutations in the HER2 tyrosine kinase have been identified in human breast cancers that lack HER2 gene amplification. These patients are not candidates for HER2 targeted drugs under current standards of care, but preclinical data strongly suggest that these patients will benefit from anti...
Na minha lista:
| Publicado no: | J Natl Compr Canc Netw |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4701428/ https://ncbi.nlm.nih.gov/pubmed/26358790 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|